When trying to increase infliximab for active disease (inflammatory arthritis or sarcoidosis), do you prefer to increase dosage or reduce frequency between doses?  

As is often the case with rheumatology therapeutics, we are residing in a " data-free" zone. There is limited literature available from the Crohn's disease patient population where this issue was studied in a limited way. There did not appear to be any significant difference in outcome...

Both approaches can be effective. To my knowledge, there are no prospective studies comparing the two options; both wind up increasing the total dose that the patient is receiving. In our infusion center, we generally increase the dose when possible, primarily for logistical reasons, as this is less...